DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Alosetron
Alosetron
FDA Warns About an Increased Risk of Serious Pancreatitis with Irritable Bowel Drug Viberzi (Eluxadoline) in Patients Without a Gallbladder
Therapeutic Class Overview Irritable Bowel Syndrome Agents
Prophylactic Antiemetic Therapy with Ondansetron, Granisetron and Metoclopramide in Patients Undergoing Laparoscopic Cholecystectomy Under GA
Antidepressants for Functional Gastrointestinal Disorders
Irritable Bowel Syndrome-Diarrhea
Efficacy of Eluxadoline in Irritable Bowel Syndrome with Diarrhea
Neuromodulators for Functional Gastrointestinal Disorders (Disorders of Gutlbrain Interaction): a Rome Foundation Working Team Report Douglas A
2015.09 IBS Drug Class Review.Pdf
Viberzi™ (Eluxadoline) – Safety Update
Drug Interactions with Tobacco Smoke: Implications for Patient Care
Hepatic Encephalopathy
Soma® ) to Alosetron (Lotronex® ): a New Treatment Be Restricted for Irritable Bowel Syndrome
Irritable Bowel Syndrome — Clinical Evaluation of Drugs for Treatment
Efficacy and Tolerability of Renzapride in Irritable Bowel Syndrome: a Meta-Analysis of Randomized, Controlled Clinical Trials Including 2528 Patients
LOTRONEX (Alosetron Hydrochloride) Tablets • Initial U.S
Viberzi® Common Name: Eluxadoline PDL Category: GI, Constipation-IBS-OIC
Alosetron Hydrochloride Tablets Or Placebo
How the FDA Manages Drug Safety with Black Box Warnings, Use Restrictions, and Drug Removal, with Attention to Gastrointestinal Medications
Top View
Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
CCHCS Care Guide: Intoxication and Withdrawal SUMMARY DECISION SUPPORT PATIENT EDUCATION/SELF-MANAGEMENT GOALS ALERTS
Serotonin Receptors and Drugs Affecting Serotonergic Neurotransmission R ICHARD A
Long-Term Efficacy and Safety of Ramosetron in the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome
Serotonin Receptors and Drugs Affecting Serotonergic Neurotransmission
Neuronal 5-HT Receptors and SERT
Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
Lotronex (Alosetron Hydrochloride)
Irritable Bowel Syndrome (IBS): Introduction
Drug Class Review Selective Serotonin Reuptake Inhibitors
Use of Combinations Comprising a Corticosteroid and a Pyrimidopyrimidine in the Treatment of Inflammatory Diseases
Brain-Gut Interactions in IBS
Alosetron (Lotronex) Reference Number: CP.CPA.65 Effective Date: 11.16.16 Last Review Date: 11.17 Revision Log Line of Business: Medicaid – Medi-Cal
Interactions with Entry & Integrase Inhibitors
Lotronex) Reference Number: CP.PMN.153 Effective Date: 11.16.16 Last Review Date: 11.20 Line of Business: Commercial, Medicaid Revision Log
5-HT Receptors and Their Ligands, Tocris Reviews No
Serotonin and Its Role in Colonic Function and in Gastrointestinal Disorders Meagan M
Efficacy of Combination Therapy with Probiotics and Mosapride In
Therapeutic Class Overview Irritable Bowel Syndrome and Constipation Agents
Protocol Revision Date 12-09-2014 Page 1 of 52 Title of the Study
Therapeutic Class Overview Irritable Bowel Syndrome and Constipation Agents
How Serotonin Level Fluctuation Affects the Effectiveness of Treatment in Irritable Bowel Syndrome
Biomedical Significance of Tryptamine
Eluxadoline | Memorial Sloan Kettering Cancer Center
Medication Coverage Policy
Pharmacology of Serotonin: What a Clinician Should Know
Pharmacotherapy for Irritable Bowel Syndrome
Drug Name Tier Level Notes Drug Name Tier Level
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
Apomorphine | Memorial Sloan Kettering Cancer Center
Irritable Bowel Syndrome and Constipation Agents
Treatment of Bacterial Overgrowth in Patients with Irritable Bowel Syndrome
Functional Gastrointestinal Disorders
Serotonergic Modulation of Visceral Sensation: Lower Gut M Camilleri
Neurotransmitter Dysfunction in Irritable Bowel Syndrome: Emerging Approaches for Management
The Use of Antidepressants in the Treatment of Irritable Bowel Syndrome and Other Functional GI Disorders Christine B
Drug-Induced Mitochondrial Dysfunction: an Emerging Model for Idiosyncratic Drug Toxicity
New Therapeutic Approaches in Irritable Bowel Syndrome
Comparative Effectiveness of 5-Hydroxytryptamine 3 Receptor Antagonists in Irritable Bowel Syndrome: a Network Meta-Analysis of Randomized Controlled Studies
Lotronex (Alosetron)
206940Orig1s000
Treatment of Irritable Bowel Syndrome SUSAN K
Lotronex (Alosetron)
The Management of Chronic Multisymptom Illness (CMI) May
Doug Drossman CV
Alosetron Tablets Selective 5-HT3 Antagonist
Gastroprokinetic Agent, Mosapride Inhibits 5-HT3 Receptor Currents in NCB-20 Cells Yong Soo Park1 and Ki-Wug Sung2,*
These Highlights Do Not Include All the Information Needed to Use ALOSETRON HYDROCHLORIDE TABLETS Safely and Effectively
Cilansetron: a Novel, High-Affinity 5-HT Receptor Antagonist For
Ramosetron for the Treatment of Irritable
(12) United States Patent (10) Patent No.: US 6,284,770 B1 Mangel Et Al
Lotronex (Alosetron Hydrochloride)
Upper GI Motility Disorders and Functional Dyspepsia
CSTI-300 (SMP-100); a Novel 5-HT3 Receptor Partial Agonist with Potential to Treat Patients with Irritable Bowel Syndrome Or Carcinoid Syndrome S
Gi Motility, Chronic – Diarrhea-Releated Diagnoses Prior Authorization Form